A significant amount of overwhelming evidence shows that patients with HER2 positive breast cancer have a worse prognosis than those with HER2 negative breast cancer, and special form of treatment is required for HER2 positive patients (Hung et al., 1986; Telli et al., 2007). This evidence concerns the gene ERBB2 and breast carcinoma.